RQ Bio

RQ Bio: Develops long-acting monoclonal antibodies to protect vulnerable people from seasonal influenza. BioTech · Series A · London, United Kingdom. Rated…

Develops long-acting monoclonal antibodies to protect vulnerable people from seasonal influenza.

Preliminary profile · public data only

Startup24 listed RQ Bio from public information on the company's own website; its founders have not claimed or verified the profile yet. The rating below is preliminary, based on public data only, and is an opinion — not investment advice. Founders can claim the profile, and anyone can report an error or request removal, on this page.

At a glance

Startup24 rating: 59/100

RQ Bio is pursuing a biologically plausible approach to a meaningful influenza-prophylaxis need among vulnerable patients, with its reported $115 million raise providing a notable credibility signal.

About the rating

Every startup on Startup24 is scored on the same six criteria — team, market, product, advantages, risk and reputation — with the reasoning written out. Founders list for free; investors subscribe to see the full analysis.

Startup24 (startup-24.com) rates startups on real, verified data: founders list for free, investors subscribe to find them first. Operated by DOTOVO OÜ, Tallinn, Estonia.